Editas Medicine Inc (EDIT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Editas Medicine Inc (EDIT) has a cash flow conversion efficiency ratio of -0.281x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.57 Million) by net assets ($105.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see EDIT stock market capitalisation for the company's overall valuation and market capitalisation.
Editas Medicine Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Editas Medicine Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Editas Medicine Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Editas Medicine Inc ranked by their cash flow conversion efficiency. Explore Editas Medicine Inc (EDIT) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hangzhou Everfine Photo E Info
SHE:300306
|
0.017x |
|
HCM II Acquisition Corp
NASDAQ:HOND
|
-0.002x |
|
Nanjing Textiles Import & Export Corp Ltd
SHG:600250
|
0.078x |
|
Hualan Group Co Ltd
SHE:301027
|
0.124x |
|
Atea Pharmaceuticals Inc
NASDAQ:AVIR
|
-0.182x |
|
Studio Dragon Corporation
KQ:253450
|
0.024x |
|
Shenzhen Glory Medical Co Ltd
SHE:002551
|
0.046x |
|
Chongqing Sansheng Building Materials Co Ltd
SHE:002742
|
0.019x |
Annual Cash Flow Conversion Efficiency for Editas Medicine Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Editas Medicine Inc from 2013 to 2025. View Editas Medicine Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.29 Million | $-165.24 Million | -6.055x | -286.66% |
| 2024-12-31 | $134.27 Million | $-210.28 Million | -1.566x | -313.62% |
| 2023-12-31 | $349.10 Million | $-132.18 Million | -0.379x | +23.00% |
| 2022-12-31 | $360.68 Million | $-177.35 Million | -0.492x | -66.19% |
| 2021-12-31 | $553.64 Million | $-163.80 Million | -0.296x | +35.25% |
| 2020-12-31 | $393.59 Million | $-179.84 Million | -0.457x | -194.86% |
| 2019-12-31 | $262.44 Million | $-40.67 Million | -0.155x | +19.93% |
| 2018-12-31 | $236.16 Million | $-45.71 Million | -0.194x | -327.65% |
| 2017-12-31 | $208.08 Million | $-9.42 Million | -0.045x | +87.80% |
| 2016-12-31 | $134.61 Million | $-49.93 Million | -0.371x | -670.56% |
| 2015-12-31 | $-83.11 Million | $-5.40 Million | 0.065x | -88.51% |
| 2014-12-31 | $-15.29 Million | $-8.65 Million | 0.566x | -64.16% |
| 2013-12-31 | $-1.76 Million | $-2.78 Million | 1.579x | -- |
About Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The… Read more